{"success":true,"data":{"pressRelease":{"id":"166197","rtpr_id":"nBw6Hsh6na-20261012","ticker":"BMY","exchange":"NYSE","all_tickers":["BMY"],"title":"Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint","author":"Business Wire","published_at":"2026-10-12T10:50:00.101Z","article_body":"Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant\nin Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint\n\nIn the trial, admilparant at the 60 mg dose demonstrated a statistically\nsignificant benefit in absolute change in forced vital capacity (FVC) from\nbaseline to Week 52 compared with placebo\n\nAdmilparant demonstrated a favorable safety and tolerability profile\n\nThe totality of the findings supports the potential of admilparant as a\nclinically meaningful first-in-class treatment\n\nBristol Myers Squibb\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.bms.com%2F&esheet=54619960&newsitemid=20261011397472&lan=en-US&anchor=Bristol+Myers+Squibb&index=1&md5=a8c27f728bc903e4dbaa6b83ebbac38b)\n(NYSE: BMY) today announced topline results from the pivotal Phase 3 ALOFT-IPF\ntrial evaluating the efficacy, safety and tolerability of admilparant, a\npotential first-in-class, orally administered, potent and selective\nlysophosphatidic acid receptor 1 (LPA(1)) antagonist, in adults with\nidiopathic pulmonary fibrosis (IPF). The trial evaluated two dose levels of\nadmilparant, 60 mg and 120 mg, twice daily for ≥52 weeks against placebo\n(1:1:1).\n\nThe trial met its primary endpoint at the 60 mg dose, with admilparant\ndemonstrating a statistically significant improvement compared to placebo in\nabsolute change in forced vital capacity (FVC) from baseline at Week 52. At\nthe 120 mg dose, admilparant slowed the decline of FVC but was not\nstatistically significant.\n\nNotably, admilparant demonstrated a well-tolerated safety profile across both\ndoses in the ALOFT-IPF trial. In both admilparant arms of the trial,\ndiscontinuations due to adverse events were low and similar to placebo.\n\n“Taken together, these topline data reinforce the profile of admilparant as\na promising, clinically meaningful investigational therapy for IPF – one\nthat reflects the innovation of targeting the LPA(1) pathway as a\nfirst-in-class approach,” said Cristian Massacesi, MD\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.bms.com%2Four-company%2Fleadership%2Fleadership-team%2Fcristian-massacesi.html&esheet=54619960&newsitemid=20261011397472&lan=en-US&anchor=Cristian+Massacesi%2C+MD&index=2&md5=a4e968381c17c505a01e5af1778b9b65)\n, executive vice president, chief medical officer and head of development,\nBristol Myers Squibb. “We also look forward to sharing the topline results\nfrom the ALOFT-PPF trial early next year, as we continue working to improve\noutcomes for patients with pulmonary fibrosis.”\n\n“IPF remains one of the most complex and challenging lung diseases to treat,\nwith unpredictable progression, irreversible scarring and a profound impact on\npatients’ daily lives,” said Fernando Martinez, MD, chair of the ALOFT\nprogram clinical steering committee and the Joseph D. Early Chair in\nBiomedical Research, interim chair and professor of medicine at UMass Chan\nMedical School. “These admilparant results represent an important\nadvancement as there remains a need for therapies that are both effective and\ntolerable for patients living with IPF.”\n\nThe company will complete a comprehensive evaluation of the Phase 3 ALOFT-IPF\ntrial data and engage with health authorities to support planned regulatory\nsubmissions, with detailed results to be presented at a future medical\nmeeting.\n\nAdmilparant is also being studied in the fully enrolled Phase 3 ALOFT-PPF\ntrial in progressive pulmonary fibrosis (PPF), with topline results\nanticipated in early 2027.\n\nBristol Myers Squibb thanks the patients and investigators who participated in\nthe ALOFT-IPF clinical trial.\n\nAbout Pulmonary Fibrosis\n\nPulmonary fibrosis\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.bms.com%2Four-science%2Fscientific-resources%2Flysophosphatidic-acid-receptor-1-in-pulmonary-fibrosis.html&esheet=54619960&newsitemid=20261011397472&lan=en-US&anchor=Pulmonary+fibrosis&index=3&md5=a5cf8ac6bab1f89fc20bec504acfe1d6)\nis a chronic, life-threatening interstitial lung disease (ILD) that occurs\nwhen lung tissue becomes irreversibly damaged and scarred, impacting how the\nlungs function. Idiopathic pulmonary fibrosis (IPF) is the most common type of\nprogressive fibrosing ILD. As an idiopathic disease, there is no identifiable\ncause, and approximately 1.4 million people live with IPF globally.\nProgressive pulmonary fibrosis (PPF) describes patients with non-idiopathic\nforms of ILD. These include connective tissue disease-related lung diseases,\nsuch as rheumatoid arthritis-associated ILD and scleroderma-associated ILD,\nand other types, such as environmental lung fibrosis, which is caused by\nexposure to dust or chemicals.\n\nMany people with pulmonary fibrosis are physically impaired, experience a\nprogressive decline in lung function, have difficulty performing simple daily\nactivities due to breathlessness and chronic cough and require continuous\nsupplemental oxygen to ease the burden of normal breathing.\n\nPulmonary fibrosis is a fatal disease with a median survival time of three to\nfive years following diagnosis and a five-year survival rate of approximately\n45%. Innovation in treatment has been limited, with very few new therapies\napproved in more than 10 years. Currently approved treatments can slow the\ndecline of lung function; however, there remains a need for additional safe\nand tolerable therapies which allow patients to manage their disease while\nthey continue to perform daily activities.\n\nAbout the Phase 3 ALOFT Trial Program\n\nALOFT-IPF (IM027-068; NCT06003426\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06003426&esheet=54619960&newsitemid=20261011397472&lan=en-US&anchor=NCT06003426&index=4&md5=ede941efe905f05c8811c48a21bfc0e7)\n) and ALOFT-PPF (IM027-1015; NCT06025578\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06025578%3Fterm%3DNCT06025578%26viewType%3DCard%26rank%3D1&esheet=54619960&newsitemid=20261011397472&lan=en-US&anchor=NCT06025578&index=5&md5=2803a6e161eb757c73e40d95018eb0f7)\n) are Phase 3, multicenter, randomized, double-blind, placebo-controlled\ntrials. ALOFT-IPF enrolled approximately 1,255 adults (≥40 years) with\nidiopathic pulmonary fibrosis (IPF), while ALOFT-PPF enrolled approximately\n1,057 adults (≥21 years) with progressive pulmonary fibrosis (PPF), with or\nwithout stable background antifibrotic therapy. The trials include both a 60\nmg and 120 mg dose arm (twice daily for ≥52 weeks) against placebo (1:1:1),\nassessing the efficacy, safety and tolerability of admilparant.\n\nThe primary endpoint for the registrational portions of the trials is absolute\nchange in forced vital capacity (FVC) from baseline to Week 52.\n\nAbout Admilparant (BMS-986278)\n\nAdmilparant is a potential first-in-class, orally administered, potent,\nselective lysophosphatidic acid receptor 1 (LPA(1)) antagonist currently being\nevaluated as a novel antifibrogenic treatment for patients with idiopathic\npulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Increased\nLPA levels and activation of LPA(1) are involved in the pathogenesis of\npulmonary fibrosis.\n\nIn a global Phase 2 trial with parallel IPF and PPF cohorts, 26 weeks of\ntreatment with admilparant 60 mg twice daily resulted in a 62% relative\nreduction in the rate of lung function decline versus placebo in patients with\nIPF and a 69% relative reduction in patients with PPF. Treatment effect was\nconsistent with or without background therapy and admilparant was well\ntolerated in both cohorts, with rates of adverse events and treatment\ndiscontinuation comparable to placebo.\n\nBristol Myers Squibb’s research approach to IPF begins not at the point\nwhere fibrosis is visible, but at its origin, where epithelial cell injury and\ndysfunctional repair first emerge. Admilparant targets three key drivers of\nfibrogenesis: faulty epithelial cell repair, inflammation/vascular leakage and\nfibroblast activation and expansion.\n\nBristol Myers Squibb: Pioneering Paths Forward in Immunology to Transform\nPatients’ Lives\n\nBristol Myers Squibb is inspired by a single vision — transforming\npatients’ lives through science. Combining our patient-centric approach and\ndeep understanding of the immune system that spans over 20 years of\nexperience, we continue to pursue bold science to deliver life-changing\nmedicines that elevate new standards of care across rheumatology, dermatology\nand pulmonology. Through our sequential immunotherapy research framework,\nwhich aims to address the root cause of disease by controlling inflammation,\nresetting the immune system and promoting immune homeostasis with the goal of\nachieving transformational efficacy, we strive to bring forward tailored\napproaches, treatments and combinations that may lead to durable remissions,\nimproved quality of life and functional cures.\n\nAbout Bristol Myers Squibb: Transforming Patients’ Lives Through Science\n\nAt Bristol Myers Squibb, our mission is to discover, develop and deliver\ninnovative medicines that help patients prevail over serious diseases. We are\npursuing bold science to define what’s possible for the future of medicine\nand the patients we serve. For more information, visit us at BMS.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.bms.com%2F&esheet=54619960&newsitemid=20261011397472&lan=en-US&anchor=BMS.com&index=6&md5=6cb049710b61cd10eac36355ad87a6ef)\nand follow us on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fbristol-myers-squibb%2Fposts%2F%3FfeedView%3Dall&esheet=54619960&newsitemid=20261011397472&lan=en-US&anchor=LinkedIn&index=7&md5=b12cad7a9e739b1442520eede99e504b)\n, X\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2Fbmsnews&esheet=54619960&newsitemid=20261011397472&lan=en-US&anchor=X&index=8&md5=6ae261b887a2c7d76ab342a337b67dc4)\n, YouTube\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.youtube.com%2Fchannel%2FUCjFf4oKibYrHae2NZ_GPS6g&esheet=54619960&newsitemid=20261011397472&lan=en-US&anchor=YouTube&index=9&md5=e34b8e26aadc079936fbd75e14248fcd)\n, Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FBristolMyersSquibb%2F&esheet=54619960&newsitemid=20261011397472&lan=en-US&anchor=Facebook&index=10&md5=c625a5fbe270b2c667c4410403e88688)\nand Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fbristolmyerssquibb%2F&esheet=54619960&newsitemid=20261011397472&lan=en-US&anchor=Instagram&index=11&md5=e39b7eac7f149dd694510b5f5e87cea0)\n.\n\nCautionary Statement Regarding Forward-Looking Statements\n\nThis press release contains “forward-looking statements” within the\nmeaning of the Private Securities Litigation Reform Act of 1995 regarding,\namong other things, the research, development and commercialization of\npharmaceutical products. All statements that are not statements of historical\nfacts are, or may be deemed to be, forward-looking statements. Such\nforward-looking statements are based on current expectations and projections\nabout our future financial results, goals, plans and objectives and involve\ninherent risks, assumptions and uncertainties, including internal or external\nfactors that could delay, divert or change any of them in the next several\nyears, that are difficult to predict, may be beyond our control and could\ncause our future financial results, goals, plans and objectives to differ\nmaterially from those expressed in, or implied by, the statements. These\nrisks, assumptions, uncertainties and other factors include, among others,\nthat future study results may not be consistent with the results to date and\nmay be unfavorable, that admilparant may not receive regulatory approval for\nthe indications described in this release, any marketing approvals, if\ngranted, may have significant limitations on their use, and, if approved,\nwhether admilparant for the indications described in this release will be\ncommercially successful. No forward-looking statement can be guaranteed.\nForward-looking statements in this press release should be evaluated together\nwith the many risks and uncertainties that affect Bristol Myers Squibb’s\nbusiness and market, particularly those identified in the cautionary statement\nand risk factors discussion in Bristol Myers Squibb’s Annual Report on Form\n10-K for the year ended December 31, 2025, as updated by our subsequent\nQuarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings\nwith the Securities and Exchange Commission. The forward-looking statements\nincluded in this document are made only as of the date of this document and\nexcept as otherwise required by applicable law, Bristol Myers Squibb\nundertakes no obligation to publicly update or revise any forward-looking\nstatement, whether as a result of new information, future events, changed\ncircumstances or otherwise.\n\ncorporatefinancial-news\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261011397472/en/\n(https://www.businesswire.com/news/home/20261011397472/en/)\n\nBristol Myers Squibb\n\nMedia Inquiries: \n\nmedia@bms.com (mailto:media@bms.com)\n\nInvestors: \n\ninvestor.relations@bms.com (mailto:investor.relations@bms.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw6Hsh6na-20261012","title":"Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint","author":"Business Wire","ticker":"BMY","created":"2026-10-12T10:50:00.101Z","tickers":["BMY"],"exchange":"NYSE","article_body":"Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant\nin Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint\n\nIn the trial, admilparant at the 60 mg dose demonstrated a statistically\nsignificant benefit in absolute change in forced vital capacity (FVC) from\nbaseline to Week 52 compared with placebo\n\nAdmilparant demonstrated a favorable safety and tolerability profile\n\nThe totality of the findings supports the potential of admilparant as a\nclinically meaningful first-in-class treatment\n\nBristol Myers Squibb\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.bms.com%2F&esheet=54619960&newsitemid=20261011397472&lan=en-US&anchor=Bristol+Myers+Squibb&index=1&md5=a8c27f728bc903e4dbaa6b83ebbac38b)\n(NYSE: BMY) today announced topline results from the pivotal Phase 3 ALOFT-IPF\ntrial evaluating the efficacy, safety and tolerability of admilparant, a\npotential first-in-class, orally administered, potent and selective\nlysophosphatidic acid receptor 1 (LPA(1)) antagonist, in adults with\nidiopathic pulmonary fibrosis (IPF). The trial evaluated two dose levels of\nadmilparant, 60 mg and 120 mg, twice daily for ≥52 weeks against placebo\n(1:1:1).\n\nThe trial met its primary endpoint at the 60 mg dose, with admilparant\ndemonstrating a statistically significant improvement compared to placebo in\nabsolute change in forced vital capacity (FVC) from baseline at Week 52. At\nthe 120 mg dose, admilparant slowed the decline of FVC but was not\nstatistically significant.\n\nNotably, admilparant demonstrated a well-tolerated safety profile across both\ndoses in the ALOFT-IPF trial. In both admilparant arms of the trial,\ndiscontinuations due to adverse events were low and similar to placebo.\n\n“Taken together, these topline data reinforce the profile of admilparant as\na promising, clinically meaningful investigational therapy for IPF – one\nthat reflects the innovation of targeting the LPA(1) pathway as a\nfirst-in-class approach,” said Cristian Massacesi, MD\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.bms.com%2Four-company%2Fleadership%2Fleadership-team%2Fcristian-massacesi.html&esheet=54619960&newsitemid=20261011397472&lan=en-US&anchor=Cristian+Massacesi%2C+MD&index=2&md5=a4e968381c17c505a01e5af1778b9b65)\n, executive vice president, chief medical officer and head of development,\nBristol Myers Squibb. “We also look forward to sharing the topline results\nfrom the ALOFT-PPF trial early next year, as we continue working to improve\noutcomes for patients with pulmonary fibrosis.”\n\n“IPF remains one of the most complex and challenging lung diseases to treat,\nwith unpredictable progression, irreversible scarring and a profound impact on\npatients’ daily lives,” said Fernando Martinez, MD, chair of the ALOFT\nprogram clinical steering committee and the Joseph D. Early Chair in\nBiomedical Research, interim chair and professor of medicine at UMass Chan\nMedical School. “These admilparant results represent an important\nadvancement as there remains a need for therapies that are both effective and\ntolerable for patients living with IPF.”\n\nThe company will complete a comprehensive evaluation of the Phase 3 ALOFT-IPF\ntrial data and engage with health authorities to support planned regulatory\nsubmissions, with detailed results to be presented at a future medical\nmeeting.\n\nAdmilparant is also being studied in the fully enrolled Phase 3 ALOFT-PPF\ntrial in progressive pulmonary fibrosis (PPF), with topline results\nanticipated in early 2027.\n\nBristol Myers Squibb thanks the patients and investigators who participated in\nthe ALOFT-IPF clinical trial.\n\nAbout Pulmonary Fibrosis\n\nPulmonary fibrosis\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.bms.com%2Four-science%2Fscientific-resources%2Flysophosphatidic-acid-receptor-1-in-pulmonary-fibrosis.html&esheet=54619960&newsitemid=20261011397472&lan=en-US&anchor=Pulmonary+fibrosis&index=3&md5=a5cf8ac6bab1f89fc20bec504acfe1d6)\nis a chronic, life-threatening interstitial lung disease (ILD) that occurs\nwhen lung tissue becomes irreversibly damaged and scarred, impacting how the\nlungs function. Idiopathic pulmonary fibrosis (IPF) is the most common type of\nprogressive fibrosing ILD. As an idiopathic disease, there is no identifiable\ncause, and approximately 1.4 million people live with IPF globally.\nProgressive pulmonary fibrosis (PPF) describes patients with non-idiopathic\nforms of ILD. These include connective tissue disease-related lung diseases,\nsuch as rheumatoid arthritis-associated ILD and scleroderma-associated ILD,\nand other types, such as environmental lung fibrosis, which is caused by\nexposure to dust or chemicals.\n\nMany people with pulmonary fibrosis are physically impaired, experience a\nprogressive decline in lung function, have difficulty performing simple daily\nactivities due to breathlessness and chronic cough and require continuous\nsupplemental oxygen to ease the burden of normal breathing.\n\nPulmonary fibrosis is a fatal disease with a median survival time of three to\nfive years following diagnosis and a five-year survival rate of approximately\n45%. Innovation in treatment has been limited, with very few new therapies\napproved in more than 10 years. Currently approved treatments can slow the\ndecline of lung function; however, there remains a need for additional safe\nand tolerable therapies which allow patients to manage their disease while\nthey continue to perform daily activities.\n\nAbout the Phase 3 ALOFT Trial Program\n\nALOFT-IPF (IM027-068; NCT06003426\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06003426&esheet=54619960&newsitemid=20261011397472&lan=en-US&anchor=NCT06003426&index=4&md5=ede941efe905f05c8811c48a21bfc0e7)\n) and ALOFT-PPF (IM027-1015; NCT06025578\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06025578%3Fterm%3DNCT06025578%26viewType%3DCard%26rank%3D1&esheet=54619960&newsitemid=20261011397472&lan=en-US&anchor=NCT06025578&index=5&md5=2803a6e161eb757c73e40d95018eb0f7)\n) are Phase 3, multicenter, randomized, double-blind, placebo-controlled\ntrials. ALOFT-IPF enrolled approximately 1,255 adults (≥40 years) with\nidiopathic pulmonary fibrosis (IPF), while ALOFT-PPF enrolled approximately\n1,057 adults (≥21 years) with progressive pulmonary fibrosis (PPF), with or\nwithout stable background antifibrotic therapy. The trials include both a 60\nmg and 120 mg dose arm (twice daily for ≥52 weeks) against placebo (1:1:1),\nassessing the efficacy, safety and tolerability of admilparant.\n\nThe primary endpoint for the registrational portions of the trials is absolute\nchange in forced vital capacity (FVC) from baseline to Week 52.\n\nAbout Admilparant (BMS-986278)\n\nAdmilparant is a potential first-in-class, orally administered, potent,\nselective lysophosphatidic acid receptor 1 (LPA(1)) antagonist currently being\nevaluated as a novel antifibrogenic treatment for patients with idiopathic\npulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Increased\nLPA levels and activation of LPA(1) are involved in the pathogenesis of\npulmonary fibrosis.\n\nIn a global Phase 2 trial with parallel IPF and PPF cohorts, 26 weeks of\ntreatment with admilparant 60 mg twice daily resulted in a 62% relative\nreduction in the rate of lung function decline versus placebo in patients with\nIPF and a 69% relative reduction in patients with PPF. Treatment effect was\nconsistent with or without background therapy and admilparant was well\ntolerated in both cohorts, with rates of adverse events and treatment\ndiscontinuation comparable to placebo.\n\nBristol Myers Squibb’s research approach to IPF begins not at the point\nwhere fibrosis is visible, but at its origin, where epithelial cell injury and\ndysfunctional repair first emerge. Admilparant targets three key drivers of\nfibrogenesis: faulty epithelial cell repair, inflammation/vascular leakage and\nfibroblast activation and expansion.\n\nBristol Myers Squibb: Pioneering Paths Forward in Immunology to Transform\nPatients’ Lives\n\nBristol Myers Squibb is inspired by a single vision — transforming\npatients’ lives through science. Combining our patient-centric approach and\ndeep understanding of the immune system that spans over 20 years of\nexperience, we continue to pursue bold science to deliver life-changing\nmedicines that elevate new standards of care across rheumatology, dermatology\nand pulmonology. Through our sequential immunotherapy research framework,\nwhich aims to address the root cause of disease by controlling inflammation,\nresetting the immune system and promoting immune homeostasis with the goal of\nachieving transformational efficacy, we strive to bring forward tailored\napproaches, treatments and combinations that may lead to durable remissions,\nimproved quality of life and functional cures.\n\nAbout Bristol Myers Squibb: Transforming Patients’ Lives Through Science\n\nAt Bristol Myers Squibb, our mission is to discover, develop and deliver\ninnovative medicines that help patients prevail over serious diseases. We are\npursuing bold science to define what’s possible for the future of medicine\nand the patients we serve. For more information, visit us at BMS.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.bms.com%2F&esheet=54619960&newsitemid=20261011397472&lan=en-US&anchor=BMS.com&index=6&md5=6cb049710b61cd10eac36355ad87a6ef)\nand follow us on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fbristol-myers-squibb%2Fposts%2F%3FfeedView%3Dall&esheet=54619960&newsitemid=20261011397472&lan=en-US&anchor=LinkedIn&index=7&md5=b12cad7a9e739b1442520eede99e504b)\n, X\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2Fbmsnews&esheet=54619960&newsitemid=20261011397472&lan=en-US&anchor=X&index=8&md5=6ae261b887a2c7d76ab342a337b67dc4)\n, YouTube\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.youtube.com%2Fchannel%2FUCjFf4oKibYrHae2NZ_GPS6g&esheet=54619960&newsitemid=20261011397472&lan=en-US&anchor=YouTube&index=9&md5=e34b8e26aadc079936fbd75e14248fcd)\n, Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FBristolMyersSquibb%2F&esheet=54619960&newsitemid=20261011397472&lan=en-US&anchor=Facebook&index=10&md5=c625a5fbe270b2c667c4410403e88688)\nand Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fbristolmyerssquibb%2F&esheet=54619960&newsitemid=20261011397472&lan=en-US&anchor=Instagram&index=11&md5=e39b7eac7f149dd694510b5f5e87cea0)\n.\n\nCautionary Statement Regarding Forward-Looking Statements\n\nThis press release contains “forward-looking statements” within the\nmeaning of the Private Securities Litigation Reform Act of 1995 regarding,\namong other things, the research, development and commercialization of\npharmaceutical products. All statements that are not statements of historical\nfacts are, or may be deemed to be, forward-looking statements. Such\nforward-looking statements are based on current expectations and projections\nabout our future financial results, goals, plans and objectives and involve\ninherent risks, assumptions and uncertainties, including internal or external\nfactors that could delay, divert or change any of them in the next several\nyears, that are difficult to predict, may be beyond our control and could\ncause our future financial results, goals, plans and objectives to differ\nmaterially from those expressed in, or implied by, the statements. These\nrisks, assumptions, uncertainties and other factors include, among others,\nthat future study results may not be consistent with the results to date and\nmay be unfavorable, that admilparant may not receive regulatory approval for\nthe indications described in this release, any marketing approvals, if\ngranted, may have significant limitations on their use, and, if approved,\nwhether admilparant for the indications described in this release will be\ncommercially successful. No forward-looking statement can be guaranteed.\nForward-looking statements in this press release should be evaluated together\nwith the many risks and uncertainties that affect Bristol Myers Squibb’s\nbusiness and market, particularly those identified in the cautionary statement\nand risk factors discussion in Bristol Myers Squibb’s Annual Report on Form\n10-K for the year ended December 31, 2025, as updated by our subsequent\nQuarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings\nwith the Securities and Exchange Commission. The forward-looking statements\nincluded in this document are made only as of the date of this document and\nexcept as otherwise required by applicable law, Bristol Myers Squibb\nundertakes no obligation to publicly update or revise any forward-looking\nstatement, whether as a result of new information, future events, changed\ncircumstances or otherwise.\n\ncorporatefinancial-news\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261011397472/en/\n(https://www.businesswire.com/news/home/20261011397472/en/)\n\nBristol Myers Squibb\n\nMedia Inquiries: \n\nmedia@bms.com (mailto:media@bms.com)\n\nInvestors: \n\ninvestor.relations@bms.com (mailto:investor.relations@bms.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-12T10:50:00.153157156Z","server_sent_at_ms":1791802200153},"received_at":"2026-10-12T10:50:00.326Z","source_url":"https://www.businesswire.com/news/home/20261011397472/en/"},"analysis":{"id":"154568","press_release_id":"166197","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":["120 mg dose missed statistical significance on the primary endpoint","Detailed data not yet disclosed; regulatory outcome remains pending"],"eventType":"clinical_trial","narrative":"Bristol Myers Squibb's pivotal Phase 3 ALOFT-IPF trial of admilparant met its primary endpoint at the 60 mg twice-daily dose, showing a statistically significant improvement in FVC change from baseline to Week 52 versus placebo.\n\nThe 120 mg dose slowed FVC decline but missed statistical significance, while safety and discontinuation rates were comparable to placebo across both doses.\n\nManagement plans to engage health authorities to support regulatory submissions and will report ALOFT-PPF topline results in progressive pulmonary fibrosis in early 2027.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Phase 3 win at 60 mg sets up first-in-class LPA(1) IPF filings, with a second PPF readout due early 2027."},"keyFigures":{"drugName":"admilparant (BMS-986278)","phaseOfTrial":"Phase 3","customDimensions":{"doses_evaluated":["60 mg","120 mg"],"primary_endpoint":"absolute change in FVC from baseline to Week 52","trial_enrollment":1255,"ipf_patients_globally":1400000,"phase2_ipf_relative_reduction":"62%","phase2_ppf_relative_reduction":"69%"}},"quotedText":"Taken together, these topline data reinforce the profile of admilparant as a promising, clinically meaningful investigational therapy for IPF","namedEntities":{"people":[{"name":"Cristian Massacesi, MD","role":"EVP, Chief Medical Officer and Head of Development, Bristol Myers Squibb"},{"name":"Fernando Martinez, MD","role":"Chair of ALOFT program clinical steering committee, UMass Chan Medical School"}],"products":["admilparant","BMS-986278"],"companies":[{"name":"Bristol Myers Squibb","ticker":"BMY"},{"name":"UMass Chan Medical School","relationship":"academic collaborator"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"Pivotal Phase 3 ALOFT-IPF trial met its primary endpoint at the 60 mg dose with statistical significance and a favorable safety profile, supporting planned regulatory submissions for a potential first-in-class IPF therapy. However, the 120 mg dose missed significance and BMY's large diversified portfolio limits single-asset impact, so not a full 5."},"tickerRelevance":{"others":[],"primary":"BMY"},"globalImportance":55,"audienceRelevance":60,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large-cap","eventGravity":"pivotal Phase 3 success, not an approval","sectorWeight":"pharma high visibility","householdBrandBoost":true}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":4,"narrative":"Bristol Myers Squibb's pivotal Phase 3 ALOFT-IPF trial of admilparant met its primary endpoint at the 60 mg twice-daily dose, showing a statistically significant improvement in FVC change from baseline to Week 52 versus placebo.\n\nThe 120 mg dose slowed FVC decline but missed statistical significance, while safety and discontinuation rates were comparable to placebo across both doses.\n\nManagement plans to engage health authorities to support regulatory submissions and will report ALOFT-PPF topline results in progressive pulmonary fibrosis in early 2027.","key_figures":{"drugName":"admilparant (BMS-986278)","phaseOfTrial":"Phase 3","customDimensions":{"doses_evaluated":["60 mg","120 mg"],"primary_endpoint":"absolute change in FVC from baseline to Week 52","trial_enrollment":1255,"ipf_patients_globally":1400000,"phase2_ipf_relative_reduction":"62%","phase2_ppf_relative_reduction":"69%"}},"named_entities":{"people":[{"name":"Cristian Massacesi, MD","role":"EVP, Chief Medical Officer and Head of Development, Bristol Myers Squibb"},{"name":"Fernando Martinez, MD","role":"Chair of ALOFT program clinical steering committee, UMass Chan Medical School"}],"products":["admilparant","BMS-986278"],"companies":[{"name":"Bristol Myers Squibb","ticker":"BMY"},{"name":"UMass Chan Medical School","relationship":"academic collaborator"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-12T10:50:05.836Z","global_importance":55,"audience_relevance":60,"importance_components":{"tickerTier":"large-cap","eventGravity":"pivotal Phase 3 success, not an approval","sectorWeight":"pharma high visibility","householdBrandBoost":true}},"durationMs":5497,"modelName":"glm-5.3-flashx"}}